ATX020 / Accent Therap - LARVOL DELTA

Inhibiting WEE1 kinase enhances sensitivity of high grade serous ovarian cancer cells to the novel KIF18A inhibitor ATX020 (AACR 2026) - "We used ATX020 resistant (A2780, PEO4, and OVCAR5) and sensitive (OVCAR3, OVCAR8, and PEO1) cell lines to examine the effects of an WEE1 inhibitor, AZD1775 (Adavosertib), on inducing CIN and thus sensitivity to ATX020. Furthermore, murine models of both resistant and sensitive HGSOC cells treated with ATX020 exhibit tumor growth inhibition that is consistent with the in vitro results. These findings suggest new research approaches that could potentially enhance the impact of KIF18A inhibition in a clinical setting."

Late-breaking abstract • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • CDK1 • KIF18A • TP53

Inhibition of KIF18A leads to mitotic arrest and robust anti-tumor activity in chromosomally instable tumors (AACR 2024) - "A proprietary tool compound, ATX020, inhibits KIF18A ATPase activity with an IC50 of 14.5 nM; KIF18A is selectively inhibited over other kinesins including CENPE (IC50 > 10 µM) and EG5 (IC50 5.87 µM)...These effects are selective, with KIF18A-independent cell lines proceeding through the cell cycle normally in the presence of inhibitors. Small molecule inhibition of KIF18A is therefore expected to have robust efficacy in solid tumors with high levels of chromosomal instability such as Ovarian cancer."

Oncology • Ovarian Cancer • Solid Tumor • ANXA5 • KIF18A